SELLAS Life Sciences Group Inc. (SLS): Price-to-Revenue Ratio

Corporate company logo of sellaslifesciences.com (SLS)

The price-to-sales ratio provided by GURU.Markets correlates with the business's dependence on the success of leukemia therapy, and 41.00 determines the current value of this metric for SELLAS Life Sciences (SLS). The strategy is based on developing peptide vaccines to combat tumors. Currently, SELLAS Life Sciences (SLS) is fully focused on the clinical trials of its pipeline, excluding any merger or acquisition deals.

sellaslifesciences.com - SLS P/S Multiple (period 07/04/2022 - 05/20/2023)

SELLAS Life Sciences (SLS) - metric breakdowns and financial figures

- current quotes and average value forecast:
Market Price sellaslifesciences.com|SLS - Price Target Chart
- stock exchange capitalization data:
Market Value SELLAS Life Sciences Group Inc.|SLS - Total Company Value
- issuer book value statistics:
Net Assets per Single Share SELLAS Life Sciences|SLS - Book Capitalization|Market Capitalization to Book Value Ratio sellaslifesciences.com|SLS - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient SELLAS Life Sciences|SLS - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital sellaslifesciences.com|SLS - Company Debts|Debt to Book Capitalization Ratio SELLAS Life Sciences Group Inc.|SLS - Company Long-Term Debts|Short-Term Debt Volume SELLAS Life Sciences|Critical Liquidity Ratio sellaslifesciences.com
- financial results and valuation multiples details:
SLS - Net Profit|Expected Net Profit SELLAS Life Sciences|SLS - Price to Earnings Ratio|Future Price to Earnings Multiple sellaslifesciences.com|SLS - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio SELLAS Life Sciences Group Inc.|SLS - Operating profit EBITDA|Net earnings per share for the last 12 months SELLAS Life Sciences|SLS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months sellaslifesciences.com|SLS - Earnings growth in current year|Expected net earnings per share growth next year SELLAS Life Sciences
- issuer revenue and sales details:
SLS - Company Revenue|Company Revenue Forecast sellaslifesciences.com|SLS - P/S Multiple|Forward Price-to-Revenue Multiple SELLAS Life Sciences Group Inc.
Fundamental company analysis:SELLAS Life Sciences Group, Inc. SLS
Core merchandise of SELLAS Life Sciences Group

The robotization of peptide synthesis and data analysis automation at SELLAS Life Sciences (SLS) are transforming the operational efficiency of oncology drug development, turning the technology stack into a core asset. By analyzing the company's historical P/S ratio, an investor determines the market value of a single dollar of revenue, which makes it possible to identify an overpayment for future growth rates or detect hidden capital accumulation by institutional investors.

Competing companies

ONC - Price to Sales|Price-to-Revenue Ratio Halozyme HALO|Revolution Medicines Inc - Price-to-Revenue Ratio|AAPG - Price-to-Revenue Ratio|CGON: Price-to-Revenue Ratio|URGN: P/S Multiple|bicara.com (BCAX) - P/S Multiple|Price-to-Revenue Ratio Personalis|Erasca Inc (ERAS) - Price-to-Revenue Coefficient|Market Cap to Revenue DCTH (Delcath)|YMAB (Y-mAbs Corp) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Aura Biosciences, Inc. AURA|Candel Therapeutics Inc. - Price-to-Revenue Ratio|Accuray - P/S Multiple|Price-to-Revenue Coefficient Actuate Therapeutics Inc. ACTU|CTOR: P/S Multiple|Price-to-Sales Ratio HURA (TuHURA Biosciences)|TARA (Protara Therapeutics) - P/S Multiple|Price to Sales fatetherapeutics.com FATE|Market Cap to Revenue WHWK (Aadi Bioscience Inc)|TCRX (tscan.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Champions Oncology, Inc. CSBR|Price-to-Revenue Coefficient XBiotech Inc (XBIT)|CEL-SCI Corp - P/S Multiple|ostherapies.com (OSTX) - Market Cap to Revenue|RADX: P/S Multiple|ARTV - Price-to-Revenue Coefficient|ANL (Adlai Nortye Ltd) - P/S Multiple|Price to Sales Veru Corporation VERU|Price-to-Revenue Ratio Tempest Therapeutics (TPST)|xiliotx.com - Market Cap to Revenue Ratio|P/S Multiple RENB (Renovaro)|MURA - Market Cap to Revenue|Kairos Pharma Inc - P/S Multiple|Price to Sales OnKure Therapeutics Inc|w2.cytomed.sg (GDTC) - Price-to-Revenue Ratio|CRIS - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Apollomics Inc.|Tharimmune Inc (THAR) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Advanced Biomed Inc (ADVB)|Price-to-Revenue Ratio GNPX (Genprex Inc)|Price-to-Revenue Ratio Calidi Biotherapeutics, Inc. CLDI|Price-to-Revenue Coefficient sunshinebiopharma.com (SBFM)|Xenetic Bio - P/S Multiple|Salarius Pharmaceuticals Inc (SLRX) - Market Cap to Revenue|PPBT: P/S Multiple|American Oncology Network, Inc. (AONC) - P/S Multiple|Price-to-Revenue Ratio BeiGene, Ltd.|Market Cap to Revenue Ratio CKPT (checkpointtx.com)|P/S Multiple ELEV|Market Cap to Revenue icadmed.com ICAD|P/S Multiple IKNA (Ikena Oncology)|Notable Labs Corp (NTBL) - Price to Sales|VIRX - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio MOR (morphosys.com)|NAYA (NAYA Biosciences Inc.) - Market Cap to Revenue|Ascentage Pharma Group International - Market Capitalization-to-Revenue Ratio